BIOLIFE SOLUTIONS INC

BLFS

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Deerfield Management Casdin Capital

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Deerfield ManagementNEWFeb 17, 2026

Shares: 120,211Value: $2.9M

# Signal Note: Deerfield Initiates BLFS Position Deerfield Management's $2.9M entry into BLFS suggests confidence in the company's cell and tissue preservation platform, which serves the regenerative medicine and transplant markets. Key catalysts to monitor include adoption rates for HypoThermosol and OrganOvo partnerships, though near-term revenue visibility remains limited given the capital-intensive nature of the cell therapy market.

Casdin CapitalNEWFeb 17, 2026

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

CI2 funds DGX2 funds ALNY2 funds LEGN2 funds GPCR2 funds RVMD2 funds TXG2 funds VCYT

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Casdin Capital Initiates $144M Position in BLFS Casdin's $144M entry into Biolife Solutions—a leading developer of cell and tissue preservation technology—signals conviction in the expanding regenerative medicine and cell therapy market. BLFS's HypoThermosol preservation platform is critical infrastructure for the growing number of CAR-T, stem cell, and organ transplant programs, with near-term catalysts including expanded hospital adoption and partnership revenues. The position sizing suggests Casdin sees durable margin expansion as cell therapy volumes scale post-2024 clinical readouts across multiple sponsored programs.